Literature DB >> 8783327

Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain.

Mikito Kawamata1, Kunihiko Ishitani, Kunitsugu Ishikawa, Hiromi Sasaki, Koichi Ota, Keiichi Omote, Akiyoshi Namiki.   

Abstract

Twenty-one patients with pancreatic cancer pain were studied to evaluate the effectiveness of celiac plexus block (CPB) on pain relief and quality of life (QOL), compared to the traditional NSAID-morphine treatment. The criteria were morphine consumption, visual analogue pain scale (VAS), performance status (PS) determined by medical and nursing staffs, and answers to QOL questionnaires. Morphine consumption, VAS, PS, and self-assessed QOL scores were taken when the administration of morphine was necessary for pain relief and those scores were used as control. Morphine consumption and the VAS score were recorded at regular weekly intervals and the PS and QOL scores were measured every 2 weeks thereafter. CPB was performed within 2-3 days after the control measurement. The VAS scores of the patients receiving CPB (n = 10) were statistically lower for the first 4 weeks after the procedure than those of the patients receiving the standard NSAID-morphine treatment (n = 11) during the same time period after the control measurement. Morphine consumption was significantly lower in weeks 4-7 (inclusive) following the procedure in the CPB group and continued to be lower thereafter, though not significantly so. Although the PS score slightly improved at the 2nd week after CPB, it was not improved by the start of the NSAID-morphine treatment. Self-assessed QOL scores did not ameliorate statistically after CPB; however, they did deteriorate remarkably in the patients treated only with morphine-NSAID during their survival periods, while they deteriorated only slightly in the CPB group. There were fewer side effects after CPB. These results indicate CPB does not directly improve QOL in patients with pancreatic cancer pain, but it may prevent deterioration in QOL by the long-lasting analgesic effect, limitation of side effects and the reduction of morphine consumption, compared to treatment only with NSAID-morphine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783327     DOI: 10.1016/0304-3959(95)00189-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  34 in total

Review 1.  Celiac block for the treatment of pancreatic pain.

Authors:  S Ischia; E Polati; G Finco; L Gottin
Journal:  Curr Rev Pain       Date:  2000

Review 2.  The Role of Ablation in Cancer Pain Relief.

Authors:  Dimitrios K Filippiadis; Steven Yevich; Frederic Deschamps; Jack W Jennings; Sean Tutton; Alexis Kelekis
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

Review 3.  Celiac plexus block for visceral pain.

Authors:  Ian Carroll
Journal:  Curr Pain Headache Rep       Date:  2006-02

Review 4.  Regional pain syndromes in cancer patients.

Authors:  H A Zekry; E Bruera
Journal:  Curr Rev Pain       Date:  2000

Review 5.  Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how?

Authors:  Jonathan M Wyse; Yen-I Chen; Anand V Sahai
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  A retrospective case series of patients who have undergone coeliac plexus blocks for the purpose of alleviating pain due to intra-abdominal malignancy.

Authors:  Alix Dumitrescu; Arun Aggarwal; Richard Chye
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-20

Review 7.  Celiac plexus block for pancreatic cancer pain in adults.

Authors:  Paolo G Arcidiacono; Giliola Calori; Silvia Carrara; Ewan D McNicol; Pier A Testoni
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

8.  What is the evidence for EUS-guided celiac plexus block/neurolysis?

Authors:  Amitabh Chak
Journal:  Gastrointest Endosc       Date:  2009-02       Impact factor: 9.427

9.  Pain management of patients with unresectable peripancreatic carcinoma.

Authors:  Rutger C I van Geenen; Claudia M G Keyzer-Dekker; Geertjan van Tienhoven; Huug Obertop; Dirk J Gouma
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

10.  Vaso-occlusive painful events in sickle cell disease: impact on child well-being.

Authors:  Amanda M Brandow; David C Brousseau; Nicholas M Pajewski; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.